lenzilumab

{
  "id": "MLC-T-ONC-014746",
  "term": "lenzilumab",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, lenzilumab binds to and neutralizes GM-CSF. This prevents GM-CSF binding to the GM-CSF receptor, which is a heterodimeric protein expressed on myeloid progenitor cells, and prevents GM-CSF-mediated signaling. This may induce apoptosis in and inhibit proliferation of cancer cells that overproduce GM-CSF. GM-CSF plays a key role in the differentiation and proliferation of monocytes, macrophages and granulocytes; elevated levels of GM-CSF are associated with certain autoimmune diseases, inflammatory diseases, and cancers.",
  "synonyms": [
    "immunoglobulin G1-kappa, anti-(homo sapiens CSF2 (colony stimulating factor 2 (granulocyte-macrophage), granulocyte macrophage colony stimulating factor, GM-CSF)), homo sapiens monoclonal antibody"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lenzilumab/"
}